DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,034 filers reported holding DANAHER CORPORATION in Q1 2023. The put-call ratio across all filers is 0.99 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $266,347,259 | +0.3% | 1,073,548 | -3.0% | 2.48% | +9.1% |
| Q2 2023 | $265,537,200 | -0.8% | 1,106,405 | +4.2% | 2.27% | -5.6% |
| Q1 2023 | $267,580,030 | -1.0% | 1,061,657 | +4.3% | 2.41% | -8.0% |
| Q4 2022 | $270,205,257 | +22.2% | 1,018,029 | +19.0% | 2.62% | +23.6% |
| Q3 2022 | $221,053,000 | +61.5% | 855,834 | +58.5% | 2.12% | +70.7% |
| Q2 2022 | $136,880,000 | -0.3% | 539,919 | +15.3% | 1.24% | +25.4% |
| Q1 2022 | $137,339,000 | -6.0% | 468,206 | +5.4% | 0.99% | +0.9% |
| Q4 2021 | $146,161,000 | -19.7% | 444,246 | -25.7% | 0.98% | -23.3% |
| Q3 2021 | $182,034,000 | +1.3% | 597,932 | -10.7% | 1.28% | -7.6% |
| Q2 2021 | $179,710,000 | +24.6% | 669,661 | +4.5% | 1.38% | +7.5% |
| Q1 2021 | $144,184,000 | +10.3% | 640,589 | +8.8% | 1.29% | -1.6% |
| Q4 2020 | $130,767,000 | +48.9% | 588,669 | +44.3% | 1.31% | -13.3% |
| Q3 2020 | $87,820,000 | +32.9% | 407,839 | +9.2% | 1.51% | +93.1% |
| Q2 2020 | $66,068,000 | +21.4% | 373,627 | -5.0% | 0.78% | -33.2% |
| Q1 2020 | $54,415,000 | +11.7% | 393,144 | +23.9% | 1.17% | +56.1% |
| Q4 2019 | $48,699,000 | +16.1% | 317,300 | +9.3% | 0.75% | +5.5% |
| Q3 2019 | $41,939,000 | -5.7% | 290,374 | -6.7% | 0.71% | -9.4% |
| Q2 2019 | $44,478,000 | +29.1% | 311,207 | +19.2% | 0.78% | +16.1% |
| Q1 2019 | $34,463,000 | +52.2% | 261,043 | +18.9% | 0.68% | +18.2% |
| Q4 2018 | $22,638,000 | -43.1% | 219,535 | -40.0% | 0.57% | -35.1% |
| Q3 2018 | $39,770,000 | +201.7% | 366,007 | +174.0% | 0.88% | +174.5% |
| Q2 2018 | $13,183,000 | +8.2% | 133,596 | +7.4% | 0.32% | -9.6% |
| Q1 2018 | $12,185,000 | -47.8% | 124,446 | -50.6% | 0.36% | -49.6% |
| Q4 2017 | $23,360,000 | -24.8% | 251,670 | -30.5% | 0.70% | -33.4% |
| Q3 2017 | $31,065,000 | +18.2% | 362,149 | +16.3% | 1.06% | +8.6% |
| Q2 2017 | $26,275,000 | +480.3% | 311,356 | +488.1% | 0.97% | +540.8% |
| Q1 2017 | $4,528,000 | +42.6% | 52,942 | +29.8% | 0.15% | +19.7% |
| Q4 2016 | $3,175,000 | -70.9% | 40,794 | -70.7% | 0.13% | -72.5% |
| Q3 2016 | $10,912,000 | -1.3% | 139,206 | +27.2% | 0.46% | -0.2% |
| Q2 2016 | $11,057,000 | -33.4% | 109,471 | -37.5% | 0.46% | -46.5% |
| Q1 2016 | $16,612,000 | -13.8% | 175,119 | -15.6% | 0.86% | +4.5% |
| Q4 2015 | $19,268,000 | +35.6% | 207,446 | +24.4% | 0.83% | +57.8% |
| Q3 2015 | $14,214,000 | +7.8% | 166,814 | +8.3% | 0.52% | -9.8% |
| Q2 2015 | $13,180,000 | +108.9% | 153,987 | +109.2% | 0.58% | +49.0% |
| Q4 2014 | $6,309,000 | -31.2% | 73,603 | -39.0% | 0.39% | -26.7% |
| Q3 2014 | $9,168,000 | +3.7% | 120,669 | +7.4% | 0.53% | -7.8% |
| Q2 2014 | $8,842,000 | -34.8% | 112,311 | -37.9% | 0.58% | -45.5% |
| Q1 2014 | $13,569,000 | +226.6% | 180,926 | +236.3% | 1.06% | +160.2% |
| Q4 2013 | $4,154,000 | -63.3% | 53,804 | -67.0% | 0.41% | -71.7% |
| Q3 2013 | $11,309,000 | -42.1% | 163,141 | -47.2% | 1.44% | -51.7% |
| Q2 2013 | $19,543,000 | – | 308,730 | – | 2.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |